NanoporeOxfordWorld News

Oxford Nanopore valued at $6.17 billion as shares soar in London debut - Financial Markets Worldwide

Please try another search

ReutersStock Markets7 minutes ago (Sep 30, 2021 04:26AM ET)

© Reuters. FILE PHOTO: A COVID-19 self-test kit is seen before being used by a teacher in Milton Keynes, Britain, January 28, 2021. REUTERS/Andrew Boyers

(Reuters) -Shares of Oxford Nanopore Technologies soared more than 45% in their market debut on Thursday, giving the biotech group a market value of $6.7 billion and showing increased investor appetite in life sciences companies listing in London.

The stock was trading at 619.9 pence by 0757 GMT and the company’s valuation was about 4.93 billion pounds ($6.74 billion). The initial public offering (IPO) price was 425 pence.

The listing marks a significant move for the London Stock Exchange as most British pharma and life science companies tend to list on New York’s Nasdaq.

“We are living on the cusp of the genomic era,” Chief Executive Gordon Sanghera said in a statement.

“Our focus remains on continuing to innovate, grow, and working towards our goal of enabling the analysis of anything, by anyone, anywhere.”

The company, which specialises in DNA sequencing and provides rapid COVID-19 tests to Britain’s national health services, sold 524 million pounds worth of shares in the IPO. It set its issue price towards the upper end of an earlier range.

The London Stock Exchange has had a strong run of IPOs in the first half of this year, with new companies raising $12.77 billion in the first seven months of 2021, the highest in seven years, according to Refinitiv data.

Oxford Nanopore had planned to issue 82.4 million new shares, raising 350 million pounds, while existing shareholders sold 41 million shares, it said in a statement.

($1 = 0.7311 pounds)

Related Articles

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button